Noticias de AIM_US

07/05/2026 AIM_US — Stock Titan

Ovarian cancer study reports 50% responses with 3-drug combo

07/05/2026 AIM_US — Yahoo Finance ES ← EN

AIM ImmunoTech anuncia una tasa de respuesta objetiva (ORR) del 50 % en el ensayo clínico de fase 2 sobre cáncer de ovario recurrente de UPMC, lo que sugiere un potencial de combinación innovador

El informe final del criterio de valoración primario de UPMC detalla datos positivos del ensayo clínico sobre cáncer de ovario que combina Ampligen, Pembrolizumab y Cisplatino Robert P. Edwards, MD, Cátedra McCall de Obstetricia, Ginecología y Ciencias Reproductivas de la Facultad de Medicina de la Universidad de Pittsburgh Robert P. Edwards, MD, Cátedra McCall de Obstetricia, Ginecología y Ciencias Reproductivas de la Facultad de Medicina de la Universidad de Pittsburgh OCALA, Florida, 7 de mayo de 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE estadounidense:

07/05/2026 AIM_US — Sahm

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

06/05/2026 AIM_US — GuruFocus

AIM ImmunoTech (STU:HXB) Dividends Received

28/04/2026 AIM_US — FinancialContent

AIM ImmunoTech Inc. Common Stock (NY: AIM

22/04/2026 AIM_US — tayninh.gov.vn

AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading. - Most Watched Stocks

22/04/2026 AIM_US — sonla.gov.vn

AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading. - Most Watched Stocks

20/04/2026 AIM_US — The National Law Review

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director